Charles Schwab Investment Management Inc. Boosts Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Charles Schwab Investment Management Inc. grew its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 12.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 538,588 shares of the company’s stock after buying an additional 58,465 shares during the period. Charles Schwab Investment Management Inc. owned 0.14% of GoodRx worth $2,504,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of GDRX. Point72 Asset Management L.P. purchased a new stake in shares of GoodRx during the third quarter valued at $11,295,000. Geode Capital Management LLC lifted its position in shares of GoodRx by 6.3% in the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock worth $6,823,000 after buying an additional 58,610 shares in the last quarter. Franklin Resources Inc. bought a new stake in GoodRx in the third quarter worth $5,675,000. Pier Capital LLC bought a new stake in GoodRx during the third quarter worth approximately $3,259,000. Finally, Bank of New York Mellon Corp increased its position in GoodRx by 10.1% during the fourth quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company’s stock valued at $896,000 after acquiring an additional 17,633 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GDRX has been the subject of a number of recent analyst reports. KeyCorp lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Mizuho started coverage on GoodRx in a report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective for the company. Morgan Stanley dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Citigroup lowered their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Wells Fargo & Company dropped their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.18.

GoodRx Trading Down 0.4 %

Shares of GDRX stock opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The firm has a market cap of $1.73 billion, a PE ratio of -150.00, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a 50-day moving average of $4.77 and a two-hundred day moving average of $5.31. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.